Jaime I Arevalo-Villalobos1, Dania O Govea-Alonso1, Elizabeth Monreal-Escalante1, Sergio Zarazúa2, Sergio Rosales-Mendoza3. 1. Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, San Luis Potosí, SLP, 78210, Mexico. 2. Laboratorio de Neurotoxicología, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, San Luis Potosí, SLP, 78210, Mexico. 3. Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, San Luis Potosí, SLP, 78210, Mexico. rosales.s@fcq.uaslp.mx.
Abstract
MAIN CONCLUSION: A recombinant antigen targeting α-synuclein was produced in the plant cell rendering an immunogenic protein capable to induce humoral responses in mice upon oral administration. Synucleinopathies are neurodegenerative diseases characterized by the abnormal accumulation of α-synuclein (α-Syn, a 140 amino acid protein that normally plays various neurophysiologic roles) aggregates. Parkinson's disease (PD) is the synucleinopathy with the highest epidemiologic impact and although its etiology remains unknown, α-Syn aggregation during disease progression pointed out α-Syn as target in the development of immunotherapies. Herein a chimeric protein, comprising the B subunit of the enterotoxin from enterotoxigenic Escherichia coli and α-Syn epitopes, was expressed in the plant cell having the potential to induce humoral responses following oral immunization. This approach will serve as the basis for the development of oral plant-based vaccines against PD with several potential advantages such as low cost, easy scale-up during production, and easy administration.
MAIN CONCLUSION: A recombinant antigen targeting α-synuclein was produced in the plant cell rendering an immunogenic protein capable to induce humoral responses in mice upon oral administration. Synucleinopathies are neurodegenerative diseases characterized by the abnormal accumulation of α-synuclein (α-Syn, a 140 amino acid protein that normally plays various neurophysiologic roles) aggregates. Parkinson's disease (PD) is the synucleinopathy with the highest epidemiologic impact and although its etiology remains unknown, α-Syn aggregation during disease progression pointed out α-Syn as target in the development of immunotherapies. Herein a chimeric protein, comprising the B subunit of the enterotoxin from enterotoxigenic Escherichia coli and α-Syn epitopes, was expressed in the plant cell having the potential to induce humoral responses following oral immunization. This approach will serve as the basis for the development of oral plant-based vaccines against PD with several potential advantages such as low cost, easy scale-up during production, and easy administration.
Authors: Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie Chilcote; Dora Games; Dale Schenk Journal: Neuron Date: 2005-06-16 Impact factor: 17.173
Authors: P Ibáñez; A-M Bonnet; B Débarges; E Lohmann; F Tison; P Pollak; Y Agid; A Dürr; A Brice Journal: Lancet Date: 2004 Sep 25-Oct 1 Impact factor: 79.321
Authors: N V Ravin; V V Kuprianov; L A Zamchuk; A V Kochetov; Yu L Dorokhov; J G Atabekov; K G Skryabin Journal: Biochemistry (Mosc) Date: 2008-10 Impact factor: 2.487
Authors: A M Walmsley; M L Alvarez; Y Jin; D D Kirk; S M Lee; J Pinkhasov; M M Rigano; C J Arntzen; H S Mason Journal: Plant Cell Rep Date: 2003-04-11 Impact factor: 4.570
Authors: Eliezer Masliah; Edward Rockenstein; Michael Mante; Leslie Crews; Brian Spencer; Anthony Adame; Christina Patrick; Margarita Trejo; Kiren Ubhi; Troy T Rohn; Sarah Mueller-Steiner; Peter Seubert; Robin Barbour; Lisa McConlogue; Manuel Buttini; Dora Games; Dale Schenk Journal: PLoS One Date: 2011-04-29 Impact factor: 3.240